| Literature DB >> 30828478 |
Reza Mohammadinejad1, Arezoo Dadashzadeh2, Saeid Moghassemi2, Milad Ashrafizadeh3, Ali Dehshahri4, Abbas Pardakhty1, Hosseinali Sassan5, Seyed-Mojtaba Sohrevardi6, Ali Mandegary7.
Abstract
Recently, carbon dots (CDs) have attracted great attention due to their superior properties, such as biocompatibility, fluorescence, high quantum yield, and uniform distribution. These characteristics make CDs interesting for bioimaging, therapeutic delivery, optogenetics, and theranostics. Photoluminescence (PL) properties enable CDs to act as imaging-trackable gene nanocarriers, while cationic CDs with high transfection efficiency have been applied for plasmid DNA and siRNA delivery. In this review, we have highlighted the precursors, structure and properties of positively charged CDs to demonstrate the various applications of these materials for nucleic acid delivery. Additionally, the potential of CDs as trackable gene delivery systems has been discussed. Although there are several reports on cellular and animal approaches to investigating the potential clinical applications of these nanomaterials, further systematic multidisciplinary approaches are required to examine the pharmacokinetic and biodistribution patterns of CDs for potential clinical applications.Entities:
Keywords: Bioimaging; Cationic carbon dots; Fluorescent; Gene delivery; Surface passivation; Theranostics
Year: 2019 PMID: 30828478 PMCID: PMC6383136 DOI: 10.1016/j.jare.2019.01.004
Source DB: PubMed Journal: J Adv Res ISSN: 2090-1224 Impact factor: 10.479
Fig. 1Heteroatom-containing compounds as precursors to produce heteroatom-doped CDs.
Fig. 2CDs are suitable nanocarriers for nucleic acid delivery.
Methodologies for the preparation of CDs.
| Strategies | Methods | Advantages | Disadvantages | Refs |
|---|---|---|---|---|
| Bottom-up | Microwave synthesis | Easily controllable size, uniform size distribution, short reaction time | High energy cost | |
| Thermal decomposition | Large-scale generation, low cost, easy operation | Broad size distribution | ||
| Hydrothermal treatment | Lack of toxicity, low cost, superior quantum efficiency | Low yield | ||
| Top-down | Laser ablation | Morphology and size control | High cost, sophisticated process | |
| Electrochemical oxidation | High purity and yield, size control | Sophisticated process | ||
| Chemical oxidation | Large-scale generation, easy process with simple tools | Broad size distribution | ||
| Ultrasonic treatment | Easy process | High energy cost | ||
Fig. 3Devices to produce CDs.
Fig. 4Cationic materials to produce positively charged CDs.
Application of CDs for image-guided gene therapy.
| Precursors and surface passivation | Synthesis method | Properties | Zeta potential | Cargo | Cell lines/animal | Major outcomes | Ref |
|---|---|---|---|---|---|---|---|
| Porphyra polysaccharide – EDA | Hydrothermal | Size: <10 nm, QY: 56.3% | 23.54 ± 1.4 mV | pDNA encoding transcription factors Asc11, Brn2 and Sox2 | EMSCs | Differentiation of stem cells to neural cells with CDs achieved faster and more efficiently than with all-trans retinoic acid, low cytotoxicity | |
| PEI and folic acid (FA) | Hydrothermal | Size: 2–9 nm, QY: 42%, uniform dispersion | +23.5 mV | Enhanced green fluorescent protein DNA plasmid (pEGFP) | 293 T, HeLa | Low cytotoxicity, bioimaging, targeted gene delivery | |
| Arginine and glucose | Microwave | Size: 1–7 nm, QY: 12.7%, high solubility, tuneable fluorescence | 25.4 ± 0.3 mV | Gene plasmid SOX9 | MEFs | Obvious chondogenic differentiation, low cytotoxicity, biocompatibility | |
| Glycerol and PEI, folate-conjugated reducible PEI | Microwave | Size: 9.0 ± 1.1 | 4.4 ± 1.7 mV | siRNA (EGFR and cyclin B1) | H460, 3T3, animal | Biocompatibility, sustained gene silencing, stimulus-responsive property | |
| Citric acid (CA), 1,2-EDA, polycation-b-polyzwitterion copolymer (PDMAEMA-b-PMPDSAH) | Microwave | Size: 2.2 ± 0.3 nm, QY: 41.5% | Depended on polymer/DNA weight ratio: from +10 mv to +35 mV | pDNA | COS-7 | High transfection efficiency, bioimaging, high haemocompatibility | |
| Tetrafluoroterephthalic acid, branched-PEI | Solvothermal | Size: 4.8 ± 0.5 nm | 12.6 ± 0.3 mV | pDNA | HEK 293 T, NIH 3T3, COS-7, HepG2, B16F10, A549, Primary 3T3-L1, mESCs | Low cytotoxicity, efficient transfection, enhanced affinity of encapsulated DNA to cytomembrane | |
| Low molecular weight amphiphilic PEI (Alkyl-PEI2k) | Laser ablation | Size: 10 nm, monodisperse | 17.33 ± 1.97 mV | siRNA and pDNA | 4T1-luc, 4T1 cells, animal | Low toxicity and good gene transfection effect | |
| PEI, 2-((dodecyloxy)methyl)oxirane | Hydrothermal | Size: 3–7 nm | +35.4 ± 1.5 mV | EGFP, siRNA, pDNA, doxorubicin (DOX) | A549 | Low cytotoxicity, high transfection efficiency, early cell apoptosis, good drug loading ability | |
| Glycerol with PEI | Microwave | Size: 5–10 nm, maximum emission: 465 nm | Approximately +30 mV | pDNA | HeLa, PC-3 | High cell viability of CD-PEI/Au-PEI carrier, high transfection efficiency (the appropriate size of the complex might facilitate cellular uptake) | |
| PEI, 2,2,3,3,4,4-hexafluoro-1,5-pentanediol diglycidyl ether | Hydrothermal | Size: 1.5–3.5 nm, QY: 5. 6% | From +30 to 40 mV | Cy5-labelled pDNA | HepG2, HeLa, 7702, A549 | High transfection efficiency and cellular uptake, good cell imaging capability under single-wavelength excitation, minimal cytotoxicity | |
| Glycerol and branched PEI | Microwave | QY: depended on microwave irradiation time | From 0 to +25 mV | pDNA | COS-7, HepG2 | Low cytotoxicity, high transfection efficiency | |
| Citric acid and branched PEI | Microwave | Size: depended on pH | At pH 1, 4 and 8, the zeta potential was +36.5 ± 6.2 mV, +51.8 ± 4.8 mV and +2.7 ± 4.4, respectively. | pDNA and siRNA | A549, A549-Luc, animal | High transfection rate, cell viability was dwindling by increasing concentration of carrier | |
| Alginate | Hydrothermal | Size: 5–10 nm, QY: 12.7% | +25 mV | Plasmid TGF-β1 | 3T6 | Exhibited strong and stable fluorescence, water-dispersible, high transfection efficiency, negligible toxicity | |
| Citric acid and tryptophan (Trp)- PEI-adsorbed CD NPs (CDs@PEI) | Microwave | Size: 3.9 ± 0.3 nm, QY: 20.6% | +26.6 ± 1.6 mV | Survivin siRNA | MGC-803 | Superior water solubility, excellent biocompatibility, enhanced gene delivery efficiency, induced efficient gene knockdown | |
| HA and PEI | Microwave | Size and QY: depended on microwave irradiation time | Increase from −5 mV to +44 mV as the weight ratio of CDs/DNA increased | pDNA | HeLa | Low cytotoxicity, high transfection efficiency, strong blue fluorescence under UV light, good intracellular imaging ability | |
| Glucose and branched or linear PEI | Hydrothermal | Size: 3.5 ± 0.9 nm, QY of CDs with branched PEI: 2.861%, with linear PEI: 2.439% | – | pDNA | HEK 293T | The branched PEI-modified CDs exhibited higher gene transfection efficiency than linear PEI and naked pDNA | |
| HA and PEI | Hydrothermal | Size: approximately 2.25 nm, QY: 12.4% | For CDs: approximately +27 mV, for CDs/pDNA: about +16 mV | pDNA | MGC-803, Hela | Biocompatibility, excellent gene condensation capability | |
| PEG and PEI | Microwave | Size: 3.7 ± 0.7 nm | +15 ± 8 mV | dsRNA of two target genes (SNF7 and SRC) | Nontoxicity, gene suppression |
Fig. 5(a1) Imaging of drug accumulation after PPD@HPAP-CDs/pDNA topical injection and IV administration after 8 h. (a2) quantitative distribution analysis and tumour imaging after treating by IV injection of PBS, HPAP/CDs/pDNA, and PPD/HPAP/CDs/pDNA. Reprinted with permission from [101]. Copyright 2018 American Chemical Society. (b1) negative control (COS-7 cells without transfection) and (b2) samples (COS-7 cells after CD-PDMA80-PMPD40/pDNA transfection). (b3) COS-7 cells enumeration test of cell mixed with CD/PDMA80/pDNA and CD/PDMA80/PMPD40/pDNA samples. Reprinted with permission from [115]. Copyright 2014 American Chemical Society.
Fig. 6Bioluminescent imaging of luciferase inhibition after fc/rPEI/CDs delivery in luciferase-expressing H460 lung carcinoma. The image of the lungs at the time of treatment (A), after 7 days (B) and after 10 days (C). Accumulation at lung region of the fc/rPEI/CDs/pooled siRNA after aerosol delivery (D), PBS as a control sample (E). (F) Gene silencing after delivery of fc/rPEI/CDs/pooled siRNA, fc/rPEI/CDs/single siRNA, and pooled siRNA in H460 for 12 h, 24 h, and 48 h. Reprinted by permission from Nature, Scientific Reports [97], Copyright 2016. Bioimaging of tumour treatment by free Cy5-siGFP and the Cy5-siGFP/PEI/CDs (G). The tumour volumes measuring after intravenous administration of PBS, PEI/CDs, free siVEGF, and siVEGF/PEI/CDs (H). Reprinted by permission from Springer, Nano Research [127], Copyright 2017.
Fig. 7Internalization mechanisms of CDs/pDNA nanocomplexes.